Abstract Library

#3081 An Atypical Presentation of a Neuroendocrine Carcinoma of Unknown Origin

Introduction: Neuroendocrine carcinomas (NEC) of unknown primary site are uncommon. Most arise from an occult/clinically undetectable primary. Primary NEC of genitourinary tract are rare. High-grade (HG) carcinoms, are rapidly growing and aggressive but usually responsive to platinum-based combination chemotherapy.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Da Silva Dias D, Gosálbez B,

Keywords: .,

#2206 Metastatic Neuroendocrine Tumor with Unknown Primary Site Presenting Simultaneously with Prostate Adenocarcinoma

Introduction: Neuroendocrine tumors (NET) arise from a variety of different organs and have a steadily increasing incidence in the last 3 decades. 13% of NETs have unknown primary sites.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Enache O, Martin S, Lambrescu I, Sirbu A, Constantin T,

Keywords: neuroendocrine, somatostatin analogs,

#1898 Over Treatment Radionuclide Therapy (PRRT) of Metastatic Neuroendocrine Neoplasm (NEN) – A Case Report.

Introduction: Over treatment radionuclide therapy (PRRT) of metastatic neuroendocrine neoplasm (NEN).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Strzelczyk J, Poczkaj K, Rosiek V, Kos-Kudła B,

Keywords: neuroendocrine neoplasm, metastases, radionuclide therapy,

#1285 Gastrointestinal Neuroendocrine Tumors of Unknown Primary Site: Report from a Series at a Single Institute

Introduction: Neuroendocrine neoplasms of unknown primary (NENs-UP) account for 10-13% of all NENs and show different biologic behavior, histologic appearance and clinical outcome.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Zilli A

Authors: Massironi S, Fanetti I, Cavalcoli F, Zilli A, Conte D,

Keywords: Neuroendocrine tumors, unknown primary,

#1237 Risk Factors for Survival from Neuroendocrine Neoplasia with Unknown Primary Tumor Site

Introduction: Neuroendocrine neoplasia (NEN) with unknown primary site (NEN-CUP) may have a poor prognosis. We evaluated the clinical presentation, therapy, outcome, and risk factors for adverse outcomes in patients with NEN-CUP.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Begum N

Authors: Begum N, Wellner U, Thorns C, Hoffmann M, Bürk C,

Keywords: outcome, NEN-CUP, surgery, survival,